These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 350593)

  • 1. The role of complement factors in acute antibody-mediated rejection of mouse skin allografts.
    Berden JH; Capel PJ; Koene RA
    Eur J Immunol; 1978 Mar; 8(3):158-62. PubMed ID: 350593
    [No Abstract]   [Full Text] [Related]  

  • 2. [Complement activation and biological activities].
    Inoue K
    Nihon Saikingaku Zasshi; 1976 Jul; 31(4):535-55. PubMed ID: 988219
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyperacute rejection of skin allografts in the mouse by the administration of alloantibody and rabbit complement.
    Koene RA; Gerlag PG; Hagemann JF; van Haelst UJ; Wijdeveld PG
    J Immunol; 1973 Aug; 111(2):520-6. PubMed ID: 4577882
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of anti-H-2K and H-2D alloantibodies in enhancement and acute antibody-mediated rejection of mouse skin allografts.
    de Waal RM; Capel PJ; Koene RA
    J Immunol; 1980 Feb; 124(2):719-23. PubMed ID: 6985936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.
    Fearon DT; Austen KF; Ruddy S
    Rheumatology; 1975; 6():2-16. PubMed ID: 1105744
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of antiserum and complement in the acute antibody-mediated rejection of mouse skin allografts in strain combinations with increasing histoincompatibility.
    Berden JH; Gerlag PG; Hagemann JF; Koene RA
    Transplantation; 1977 Sep; 24(3):175-82. PubMed ID: 339430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
    Dennert G; Anderson CG; Warner J
    J Immunol; 1986 Jun; 136(11):3981-6. PubMed ID: 3517162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosynthesis of complement components.
    McPhaden AR; Lappin D; Whaley K
    J Clin Lab Immunol; 1982 May; 8(1):1-8. PubMed ID: 7047744
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship of functional levels of early components of complement to the H-2 complex of mice.
    Goldman MB; Goldman JN
    J Immunol; 1976 Nov; 117(5 Pt 1):1584-8. PubMed ID: 1002990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct activation of complement by trypanosomes.
    Sheppard J; Nielsen K; Tizard I; Holmes W
    J Parasitol; 1978 Jun; 64(3):544-6. PubMed ID: 351160
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of alloantibodies on corneal allograft survival.
    Hegde S; Mellon JK; Hargrave SL; Niederkorn JY
    Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1012-8. PubMed ID: 11923241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EAC4 and EAC14 production without purified Ci.
    Linscott WD
    J Immunol; 1975 Dec; 115(6):1625-30. PubMed ID: 241767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction.
    Pinckard RN; Olson MS; Giclas PC; Terry R; Boyer JT; O'Rourke RA
    J Clin Invest; 1975 Sep; 56(3):740-50. PubMed ID: 808560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental aspects of complement components in the newborn. The presence of complement components and C3 proactivator (properdin factor B) in human colostrum.
    Ballow M; Fang F; Good RA; Day NK
    Clin Exp Immunol; 1974 Oct; 18(2):257-66. PubMed ID: 4478765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venom of the ant Pseudomyrmex sp.: further characterization of two factors that affect human complement proteins.
    Schultz DR; Arnold PI
    J Immunol; 1977 Nov; 119(5):1690-9. PubMed ID: 410881
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of specific antibody on antibody-independent interactions between E. coli J5 and human complement.
    Betz SJ; Page N; Estrade C; Isliker H
    J Immunol; 1982 Feb; 128(2):707-11. PubMed ID: 7033382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new in vitro test evaluating anti-lymphocyte serum potency.
    Bach JF; Dardenne M; Dormont J; Antoine B
    Transplant Proc; 1969 Mar; 1(1):403-7. PubMed ID: 4944250
    [No Abstract]   [Full Text] [Related]  

  • 18. Mitigation of Graft-versus-host disease in mice with xenogeneic antithymocyte serum and complement.
    Volf D; Sensenbrenner LL; Santos GW
    Exp Hematol; 1976 Nov; 4(6):354-64. PubMed ID: 11110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization.
    Wu GD; He Y; Chai NN; Toyoda M; Dunn R; Kehry MR; Klein AS; Jordan SC
    Transpl Immunol; 2008 Jul; 19(3-4):178-86. PubMed ID: 18595710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.